Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07212933) titled 'The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).
Primary Sponsor: Chinese PLA General Hospital
Condition:
Gastric (Stomach) Cancer
Biological Therapy
Immunotherapy
Intervention:
Biological: RetroNectin active Killer cells
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: July 1, 2025
Target Sample Size: 90
Countries of Recruitmen...